We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

PGE Synthase

PGE synthase inhibitors act on the terminal enzymes that convert prostaglandin H2 into prostaglandin E2. Microsomal prostaglandin E (PGE) synthase-1 (mPGES-1) was described in 1999 as a glutathione-dependent enzyme induced by inflammatory stimuli. Inhibitors of this enzyme reduce prostaglandin E2 formation without blocking the upstream cyclooxygenases. MF63 and mPGES1-IN-3 are mPGES-1 inhibitors for inflammation and pain research. The list also covers the prostaglandin D synthases, which turn the same precursor into prostaglandin D2. Hematopoietic prostaglandin D synthase (H-PGDS) was cloned and its crystal structure solved in 1997. HPGDS inhibitor 1 and hPGDS-IN-1 target H-PGDS, whereas AT 56 inhibits lipocalin-type prostaglandin D synthase (L-PGDS).

1 Item

  • 16-Phenoxy tetranor Prostaglandin E2
    Cat. No.
    A63410
    CAS No.
    54382-74-0

    16-Phenoxy tetranor Prostaglandin E2

    Synonyms: 16-Phenoxy tetranor PGE2

    16-Phenoxy tetranor Prostaglandin E2 is an analog of prostaglandin E2 (PGE2) that serves as a potent modulator of various biological processes. This compound exhibits significant biological activity by influencing the prostaglandin pathway, making it valuable for studying inflammatory responses and reproductive biology. Additionally, its role as a minor metabolite of sulprostone in human plasma provides insights into pharmacokinetics and metabolic pathways relevant to drug development and therapeutic applications.

    In stock View Details
    1 mg
    $115.00
    5 mg
    $505.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...